{
    "Trade/Device Name(s)": [
        "HemosIL von Willebrand Factor Antigen"
    ],
    "Submitter Information": "Instrumentation Laboratory Company",
    "510(k) Number": "K223402",
    "Predicate Device Reference 510(k) Number(s)": [
        "K200033"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GGP"
    ],
    "Summary Letter Date": "December 9, 2022",
    "Summary Letter Received Date": "November 9, 2022",
    "Submission Date": "November 8, 2022",
    "Regulation Number(s)": [
        "21 CFR 864.7290"
    ],
    "Regulation Name(s)": [
        "Factor Deficiency Test"
    ],
    "Analyte Class(es)": [
        "hematology",
        "coagulation"
    ],
    "Analyte(s)": [
        "von Willebrand Factor Antigen"
    ],
    "Specimen Type(s)": [
        "Citrated plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ACL Elite",
        "ACL Elite Pro",
        "ACL TOP Family",
        "ACL TOP Family 50 Series"
    ],
    "Method(s)/Technology(ies)": [
        "Latex enhanced immunoassay",
        "Immunoturbidimetric assay"
    ],
    "Methodologies": [
        "Immunoturbidimetric assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for HemosIL von Willebrand Factor Antigen latex immunoassay for quantification of VWF:Ag in citrated plasma on IL Coagulation Systems",
    "Indications for Use Summary": "Automated latex enhanced immunoassay for the quantitative determination of von Willebrand Factor Antigen in human citrated plasma on IL Coagulation Systems",
    "fda_folder": "Hematology"
}